NATHALIE CASSOUX

 

NATHALIE CASSOUX

Nathalie Cassoux MD, PhD
Nationality France and Switzerland
Ophthalmologist Chair ocular oncology
Head of department of surgical oncology, Institut Curie, Paris, France
Professor of Ophthalmology (2015) Paris V Descartes
Habilitation to lead research (2014) Paris 6
Thesis of Science bio informatics (2002) Paris 13
Masters in cell oncogenesis Paris 11 (1997)
Qualified in Ophthalmology (1994) Paris 6
MD (1994) Paris 6

Nathalie Cassoux is head of the Surgical Oncology Department at Institut Curie in Paris. She obtained MD degrees at Pierre et Marie Curie Paris 6 university and a PhD thesis in bioinformatics working on neural network. She is full professor in Ophthalmology, chair ocular oncology at the University Paris 5 Descartes She is in the board of the French Society of Ophtalmology (SFO) and past president of the European Oncology Group (OOG). She’s author or coauthor of 132 peer-reviewed articles H 30.Clinical activities are focused on ocular tumors (retinoblastoma, uveal melanoma, conjunctival and eyelids tumors and ocular lymphoma. The research interests are focused on translational ocular oncology (genetic of ocular tumors, animal models, preclinical assessment). He coordinates at Institut Curie a research team on orthotopic xenografted models of ocular tumors and participates to multidisciplinary group of scientists and doctors devoted to uveal melanoma and retinoblastoma research.

Last significant publication:
1: Dehainault C, Golmard L, Millot GA, Charpin A, Laugé A, Tarabeux J, Aerts I, Cassoux N, Stoppa-Lyonnet D, Gauthier-Villars M, Houdayer C. Mosaicism and prenatal diagnosis options: insights from retinoblastoma. Eur J Hum Genet. 2016 Dec 21.
2: Assayag F, Nicolas A, Vacher S, Dehainault C, Bieche I, Meseure D, Aerts I, Cassoux N, Houdayer C, Doz F, Decaudin D. Combination of Carboplatin and Bevacizumab Is an Efficient Therapeutic Approach in Retinoblastoma Patient-Derived Xenografts. Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4916-4926.
3: Cassoux N, Thuleau A, Assayag F, Aerts I, Decaudin D. Establishment of an Orthotopic Xenograft Mice Model of Retinoblastoma Suitable for Preclinical Testing. Ocul Oncol Pathol. 2015 Apr;1(3):200-6. doi: 10.1159/000370156. Review.
4: Eloy P, Dehainault C, Sefta M, Aerts I, Doz F, Cassoux N, Lumbroso le Rouic L, Stoppa-Lyonnet D, Radvanyi F, Millot GA, Gauthier-Villars M, Houdayer C. A Parent-of-Origin Effect Impacts the Phenotype in Low Penetrance Retinoblastoma Families Segregating the c.1981C>T/p.Arg661Trp Mutation of RB1. PLoS Genet. 2016 Feb 29;12(2)
5: Lumbroso-Le Rouic L, Aerts I, Hajage D, Lévy-Gabriel C, Savignoni A, Algret N, Cassoux N, Bertozzi AI, Esteve M, Doz F, Desjardins L. Conservative treatment of retinoblastoma: a prospective phase II randomized trial of neoadjuvant chemotherapy followed by local treatments and chemothermotherapy. Eye (Lond). 2016 Jan;30(1):46-52
6: Dehainault C, Garancher A, Castéra L, Cassoux N, Aerts I, Doz F, Desjardins L, Lumbroso L, Montes de Oca R, Almouzni G, Stoppa-Lyonnet D, Pouponnot C, Gauthier-Villars M, Houdayer C. The survival gene MED4 explains low penetrance retinoblastoma in patients with large RB1 deletion. Hum Mol Genet. 2014 Oc

Top